Janet Wolter

16.8k total citations · 2 hit papers
30 papers, 12.3k citations indexed

About

Janet Wolter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Janet Wolter has authored 30 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Genetics. Recurrent topics in Janet Wolter's work include Cancer Treatment and Pharmacology (8 papers), Estrogen and related hormone effects (8 papers) and Breast Cancer Treatment Studies (5 papers). Janet Wolter is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Estrogen and related hormone effects (8 papers) and Breast Cancer Treatment Studies (5 papers). Janet Wolter collaborates with scholars based in United States, United Kingdom and Germany. Janet Wolter's co-authors include Steven Shak, Dennis J. Slamon, Virginia Paton, W. Eiermann, Alex Bajamonde, José Baselga, Brian Leyland‐Jones, Mark D. Pegram, Thomas Fleming and Larry Norton and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Janet Wolter

30 papers receiving 11.9k citations

Hit Papers

Use of Chemotherapy plus ... 1999 2026 2008 2017 2001 1999 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
    2001 8.4k citations Dennis J. Slamon, Brian Leyland‐Jones et al. New England Journal of Medicine profile →
  2. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
    1999 2.2k citations Melody Cobleigh, Charles L. Vogel et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janet Wolter United States 19 9.2k 4.1k 3.2k 2.9k 2.3k 30 12.3k
Alex Bajamonde United States 7 6.8k 0.7× 3.0k 0.7× 2.9k 0.9× 2.2k 0.7× 1.8k 0.8× 7 9.7k
Virginia Paton United States 19 9.9k 1.1× 4.6k 1.1× 3.5k 1.1× 2.6k 0.9× 2.6k 1.1× 31 13.3k
Tadeusz Pieńkowski Poland 39 9.6k 1.0× 3.3k 0.8× 2.0k 0.6× 3.8k 1.3× 2.5k 1.1× 129 12.0k
P. Fumoleau France 61 9.6k 1.0× 2.3k 0.6× 3.3k 1.0× 4.4k 1.5× 2.7k 1.1× 326 14.3k
Aňa Lluch Spain 55 10.3k 1.1× 2.7k 0.7× 4.1k 1.3× 6.1k 2.1× 2.5k 1.1× 306 14.7k
Stephen Chan United Kingdom 47 7.5k 0.8× 1.8k 0.5× 3.8k 1.2× 2.7k 0.9× 2.6k 1.1× 194 11.2k
Semiglazov Vf Russia 46 8.5k 0.9× 2.5k 0.6× 2.1k 0.6× 5.6k 1.9× 2.1k 0.9× 239 11.9k
Kimberly Blackwell United States 50 6.0k 0.7× 2.0k 0.5× 2.1k 0.7× 1.9k 0.6× 2.4k 1.0× 138 9.2k
Young‐Hyuck Im South Korea 51 8.7k 0.9× 2.5k 0.6× 2.9k 0.9× 3.8k 1.3× 3.7k 1.6× 270 12.4k
Nicholas J. Robert United States 44 6.7k 0.7× 1.8k 0.4× 2.0k 0.6× 4.1k 1.4× 2.0k 0.8× 181 10.0k

Countries citing papers authored by Janet Wolter

Since Specialization
Citations

This map shows the geographic impact of Janet Wolter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Wolter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Wolter more than expected).

Fields of papers citing papers by Janet Wolter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Wolter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Wolter. The network helps show where Janet Wolter may publish in the future.

Co-authorship network of co-authors of Janet Wolter

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Wolter. A scholar is included among the top collaborators of Janet Wolter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Wolter. Janet Wolter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Slamon, Dennis J., Brian Leyland‐Jones, Steven Shak, et al.. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine. 344(11). 783–792. 8436 indexed citations breakdown →
3.
Cobleigh, Melody, Charles L. Vogel, Debu Tripathy, et al.. (1999). Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. Journal of Clinical Oncology. 17(9). 2639–2639. 2174 indexed citations breakdown →
4.
Buzdar, Aman U., W. Jonat, Anthony Howell, et al.. (1998). Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer. 83(6). 1142–1152. 129 indexed citations
5.
Buzdar, Aman U., W. Jonat, Anthony Howell, et al.. (1998). Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Cancer. 83(6). 1142–1152. 143 indexed citations
6.
Andersen, Janet W., D. C. Tormey, Edward G. Mansour, et al.. (1994). Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen. Cancer. 73(2). 354–361. 51 indexed citations
7.
Bagdade, John D., Janet Wolter, Papasani V. Subbaiah, & Will G. Ryan. (1990). Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition. The Journal of Clinical Endocrinology & Metabolism. 70(4). 1132–1135. 88 indexed citations
8.
9.
Winter, Jane N., Paul S. Ritch, Steven T. Rosen, et al.. (1990). Phase II Trial of Methylglyoxal-Bis (guanylhydrazone) (MGBG) in Patients with Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group (ECOG) Study. Cancer Investigation. 8(2). 143–146. 1 indexed citations
10.
Finkelstein, Dianne M., Barrie R. Cassileth, Philip Bonomi, et al.. (1988). A Pilot Study of the Functional Living Index-Cancer (FLIC) Scale for the Assessment of Quality of Life for Metastatic Lung Cancer Patients. American Journal of Clinical Oncology. 11(6). 630–633. 84 indexed citations
11.
Arseneau, James C., Janet Wolter, Mario Kuperminc, & John C. Ruckdeschel. (1983). A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma. Investigational New Drugs. 1(3). 239–242. 29 indexed citations
12.
Fisher, Bernard, Carol Redmond, D. Lawrence Wickerham, et al.. (1983). Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Research and Treatment. 3(4). 355–364. 25 indexed citations
13.
Schoenfeld, David, Charles Rosenbaum, John Horton, et al.. (1982). A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 50(12). 2757–2762. 128 indexed citations
14.
Block, Margaret, Philip Bonomi, Janet Wolter, et al.. (1981). Treatment of stage D prostatic carcinoma with megestrol acetate. Journal of Surgical Oncology. 17(4). 367–371. 12 indexed citations
15.
Taylor, Samuel G. & Janet Wolter. (1981). Adriamycin, vincristine, dibromodulcitol, and hexamethylmelamine in advanced previously treated breast cancer: An ECOG pilot study. Medical and Pediatric Oncology. 9(2). 187–189. 2 indexed citations
16.
Costanza, Mary E., Larry Nathanson, David Schoenfeld, et al.. (1977). Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer. 40(3). 1010–1015. 70 indexed citations
17.
Costanza, Mary E., Larry Nathanson, Janet Wolter, et al.. (1976). Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma. Cancer. 37(4). 1654–1659. 11 indexed citations
18.
Costanza, Mary E., Larry Nathanson, Raymond E. Lenhard, et al.. (1972). Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea. Cancer. 30(6). 1457–1461. 41 indexed citations
19.
Slayton, Robert E., et al.. (1971). Clinical study with bleomycin. Cancer. 28(5). 1142–1146. 59 indexed citations
20.
Nathanson, Larry, Janet Wolter, John Horton, et al.. (1971). Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma. Clinical Pharmacology & Therapeutics. 12(6). 955–962. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Bajamonde Breakdown of academic impact, for papers by Virginia Paton Breakdown of academic impact, for papers by Tadeusz Pieńkowski Breakdown of academic impact, for papers by P. Fumoleau Breakdown of academic impact, for papers by Aňa Lluch Breakdown of academic impact, for papers by Stephen Chan Breakdown of academic impact, for papers by Semiglazov Vf Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by Young‐Hyuck Im Breakdown of academic impact, for papers by Nicholas J. Robert
Rankless by CCL
2026